Technology Bundle ID: TAB-2611

Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis

Request More Info
Licensing Contact:
Primary Inventors: 
James Posey (CDC)
Co-Inventors: 
Jonas Winchell (CDC), Kelley Cowart (CDC), Melissa Ramirez (CDC)
Therapeutic Area: 
Infectious Disease
Application: 
Diagnostics
Development Status: 
  • Early-stage
  • In vitro data available
Institute or Center: 
CDC

CDC scientists have developed a rapid, sensitive, and specific real-time PCR assay that is capable of detecting the presence of Mycobacterium tuberculosis and determining its resistance profile to antibiotics, such as rifampicin and isoniazid. Currently, there are few assays available that are capable of both detecting M. tuberculosis and determining the bacteria's drug resistance. This assay incorporates multiple fluorescent chemistries, providing a simple and cost-effective method of determining the bacteria's drug resistance. Additionally, this assay may be used to quickly discriminate Mycobacterium tuberculosis complex (MTBC) strains from non-MTBC strains.

Applications:
  • Rapid screening of potential multi-drug-resistant M. tuberculosis
  • Kits for diagnosis of M. tuberculosis
  • Public health programs combating emerging drug-resistance in M. tuberculosis; clinics working with at-risk populations
Advantages:
  • Robust and inexpensive way to detect dominant M. tuberculosis mutations
  • Rapid results within 5 hours of obtaining DNA
  • More cost-efficient and less complex than culturing and sequencing methods of determining drug-resistant status

Patents

PCT Application PCT/US2011/035217
Filed on 2011-05-04
US Application 13/695,935
Filed on 2012-11-02
US Application 14/703,019
Filed on 2015-05-04
US Application 61/331,189
Filed on 2010-05-04

Publications

Ramirez MV, et al.
PMID 20810777

Updated

Aug 13, 2013

Data Source: 
tts